Lexeo Therapeutics (LXEO) said Wednesday it has seen "positive" interim data from a phase 1/2 trial of LX1001 to treat APOE4-associated Alzheimer's disease.
Treatment with the gene therapy candidate resulted in "dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes," the company said.
The candidate drug also showed a "favorable safety profile," the company said.
Lexeo said it has started engagement with the US Food and Drug Administration on the results and plans to provide an update on interactions with the regulator and more LX1001 development plans next year.
The company's shares fell nearly 10% in recent trading.
Price: 8.98, Change: -0.99, Percent Change: -9.93
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。